Pure Inc

HEALTH CENTER PROGRAM

MEAT AND POULTRY PROCESSING EXPANSION PROGRAM GRANTS - ARP

CAPITAL DEVELOPMENT

PHASE II CLINICAL TESTING OF HEMOGLOBIN-BASED OXYGEN CARRIER-201 FOR USE IN THE TREATMENT OF TRAUMA

CANNABIDIOL/PALMITOYLETHANOLAMIDE SUBLINGUAL TABLETS FOR THE TREATMENT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY - PROJECT SUMMARY/ABSTRACT PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) IS A SEVERE AND DEBILITATING NERVE DYSFUNCTION PREVALENT IN OVER 30 MILLION US DIABETIC PATIENTS. IT ADVERSELY AFFECTS PATIENTS BY CAUSING SENSORY PAIN IN THE LOWER LIMBS, MUSCULAR WEAKNESS, PREDISPOSITION TO FALLS, DECREASED QUALITY OF LIFE, AND SIGNIFICANT PATIENT MORBIDITY AS A RESULT OF FOOT ULCERATIONS, AMPUTATIONS, AND DISABILITY. PDPN IS ESTIMATED TO COST $10.9 BILLION PER YEAR IN THE US ALONE, WITH MOST COSTS ATTRIBUTED TO THE TREATMENT OF FOOT ULCERS AND SUPERIMPOSED INFECTIONS. TREATMENT FOR PDPN REMAINS LIMITED DESPITE THE SIGNIFICANT ECONOMIC AND MEDICAL IMPACT ON PATIENTS AND THE U.S. HEALTHCARE SYSTEM. ESTABLISHED GUIDELINES ADVOCATE THE USE OF THERAPIES TARGETING THE SYMPTOMS OF PDPN, AND MAY INCLUDE ADMINISTRATION OF ANTICONVULSANTS, ANTIDEPRESSANTS, AND OPIOIDS, AS FIRST-LINE THERAPIES. YET, THESE THERAPIES ONLY OFFER MODERATE PAIN RELIEF, WITH ADVERSE EVENTS OUTWEIGHING PAIN REDUCTION. THE FDA HAS APPROVED VIRTUALLY NO NEW CATEGORIES OF ANALGESICS FOR THE TREATMENT OF NEUROPATHIC PAIN OVER THE LAST TWO DECADES, CREATING A GAPING HOLE IN THE DEVELOPMENT OF EFFECTIVE AND SAFE PDPN-SPECIFIC ALTERNATIVE THERAPIES. THIS PROJECT INTRODUCES A SIGNIFICANT INNOVATION IN THE TREATMENT OF PDPN THROUGH OUR CLINICALLY-DEMONSTRATED NOVEL WATER-SOLUBILIZED CANNABIDIOL-PALMITOYLETHANOLAMIDE (CBD-PEA) TECHNOLOGY. THE FORMULATION AVOIDS FIRST-PASS METABOLISM AND MEDIATES MULTIPLE PAIN PATHWAYS TO PROVIDE THE BEST ANTI-INFLAMMATORY AND ANTIOXIDANT CLINICAL OUTCOMES. OUR CBD-PEA DRUG MAY ELIMINATE THE ADVERSE EFFECTS OF CURRENT THERAPIES, THEREFORE ALLOWING ALL OR NEARLY ALL PDPN PATIENTS TO EXPERIENCE PAIN RELIEF INSTEAD OF ONLY 50% OF THE PATIENTS. PURE GREEN PHARMACEUTICALS (THE COMPANY) HAS SHOWN PRELIMINARY SUCCESS IN PUBLISHED CLINICAL DATA DEMONSTRATING THAT SUBLINGUAL ADMINISTRATION OF LOW-DOSE, WATER-SOLUBILIZED SUBLINGUAL TABLETS CONTAINING CBD (60 MG/DAY) AND PEA (300 MG/DAY), TO PATIENTS WITH CHRONIC DIABETIC NEUROPATHY, SIGNIFICANTLY REDUCED PAIN, IMPROVED SLEEP QUALITY, AND REDUCED ANXIETY [P< 0.0001 IN AN OPEN-LABEL TRIAL, N=31]. SIMILAR RESULTS WERE SEEN IN A CONFIRMATORY DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [P<0.0001, N=54]. NO ADVERSE EVENTS WERE REPORTED. THE PROPOSED PROJECT SUBSTANTIALLY EXPANDS THE COMPANY’S CAPABILITIES DEMONSTRATED IN TWO RECENTLY PUBLISHED FOUNDATIONAL PHASE 2 CLINICAL TRIALS THAT STRONGLY SUGGESTED CLINICAL AND STATISTICAL EVIDENCE FOR THE EFFICACY AND SAFETY OF CBD-PEA IN PDPN. THIS STUDY WILL DETERMINE THE IMPACT AND EFFICACY OF THE COMPANY’S WATER-SOLUBLE 20 MG CBD AND MICRONIZED 100 MG PEA SUBLINGUAL TABLET IN PATIENTS SUFFERING FROM PDPN. THIS DIRECT-TO-PHASE II IS A MILESTONE-DRIVEN CLINICAL TRIAL TO VALIDATE THE EFFICACY OF PG PHARMA’S UNIQUE FORMULATION IN PDPN REDUCTION, BY MEASURING PAIN REDUCTION, PATIENTS’ ANXIETY AND SLEEP QUALITY COMPARED TO PLACEBO CONTROL. THIS 12-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DECENTRALIZED TRIAL WILL ENROLL 200 PATIENTS ACROSS THE UNITED STATES.

AMERICAN RESCUE PLAN ACT FUNDING FOR HEALTH CENTERS

SBIR FAST-TRACK: SCALING UP PRESSURE-DRIVEN DISTILLATION FOR ULTRAPURE WATER PRODUCTION -THE BROADER COMMERCIAL IMPACT OF THIS SMALL BUSINESS INNOVATION RESEARCH(SBIR) FAST-TRACK PHASE I PROJECT IS TO IMPROVE THE EFFICIENCY AND RELIABILITY OF WATER PURIFICATION PROCESSES IN ADVANCED MANUFACTURING, PARTICULARLY IN THE SEMICONDUCTOR INDUSTRY, WHILE ADDRESSING THE GROWING CHALLENGES OF GLOBAL WATER SCARCITY. SEMICONDUCTOR FABRICATION REQUIRES LARGE VOLUMES OF ULTRAPURE WATER, WHICH IS PRODUCED USING EXTENSIVE FILTRATION AND CHEMICAL TREATMENT TO REMOVE CONTAMINANTS THAT CAN AFFECT MANUFACTURING YIELD AND PRODUCT RELIABILITY. CURRENT METHODS, SUCH AS REVERSE OSMOSIS, REQUIRE SIGNIFICANT PRE- AND POST-TREATMENT, INCREASING COSTS, ENERGY CONSUMPTION, AND OPERATIONAL COMPLEXITY. THIS PROJECT AIMS TO DEVELOP A NEW MEMBRANE TECHNOLOGY THAT USES APPLIED PRESSURE TO INDUCE DISTILLATION, ALLOWING FOR THE REMOVAL OF DIFFICULT-TO-FILTER CONTAMINANTS WHILE REDUCING THE NEED FOR CHEMICAL ADDITIVES AND ADDITIONAL PROCESSING STEPS. IN ADDITION TO BENEFITING SEMICONDUCTOR MANUFACTURING, THIS TECHNOLOGY HAS THE POTENTIAL TO IMPROVE DESALINATION AND WASTEWATER REUSE, PROVIDING A MORE EFFICIENT AND SCALABLE SOLUTION FOR PRODUCING CLEAN WATER IN REGIONS FACING WATER SHORTAGES. BY SIMPLIFYING WATER PURIFICATION, REDUCING ENERGY CONSUMPTION, AND ELIMINATING COSTLY CHEMICAL TREATMENTS, THIS INNOVATION COULD LOWER OPERATING COSTS FOR INDUSTRIAL WATER USERS, SUPPORT DOMESTIC SEMICONDUCTOR PRODUCTION, AND HELP ADDRESS CRITICAL WATER CHALLENGES WORLDWIDE. THIS PROJECT INTRODUCES A NOVEL PRESSURE-DRIVEN DISTILLATION MEMBRANE THAT ENABLES WATER PURIFICATION WITHOUT THE NEED FOR HIGH THERMAL ENERGY INPUT OR EXTENSIVE CHEMICAL PRE-TREATMENT. UNLIKE TRADITIONAL FILTRATION MEMBRANES, THIS APPROACH USES APPLIED PRESSURE TO DRIVE PHASE SEPARATION, SELECTIVELY REMOVING CONTAMINANTS SUCH AS BORON, UREA, SILICA, AND DISINFECTION BYPRODUCTS THAT ARE DIFFICULT TO FILTER WITH EXISTING MEMBRANE TECHNOLOGIES. THE RESEARCH WILL FOCUS ON OPTIMIZING MEMBRANE FABRICATION, ASSESSING SELECTIVITY AND DURABILITY UNDER OPERATIONAL CONDITIONS, AND INTEGRATING THE MEMBRANE INTO A SCALABLE MODULE SUITABLE FOR SEMICONDUCTOR MANUFACTURING, DESALINATION, AND WASTEWATER REUSE APPLICATIONS. EXPERIMENTAL VALIDATION WILL INCLUDE PERFORMANCE TESTING UNDER INDUSTRIALLY RELEVANT CONDITIONS, LONG-TERM STABILITY ANALYSIS, AND PILOT-SCALE TESTING WITH INDUSTRY PARTNERS. THIS WORK WILL ADVANCE THE DEVELOPMENT OF A NEXT-GENERATION MEMBRANE SYSTEM CAPABLE OF IMPROVING WATER QUALITY WHILE REDUCING CHEMICAL USAGE AND OPERATIONAL COMPLEXITY IN HIGH-TECH MANUFACTURING SECTORS AND LARGE-SCALE WATER TREATMENT FACILITIES. IF SUCCESSFUL, THIS TECHNOLOGY WILL OFFER A MORE EFFICIENT AND SUSTAINABLE APPROACH TO WATER PURIFICATION, BENEFITING INDUSTRIES AND COMMUNITIES THAT RELY ON CLEAN WATER FOR PRODUCTION AND DAILY USE. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE NOT PLANNED FOR THIS AWARD.

TO CONDUCT APPROVED MARKET DEVELOPMENT ACTIVITIES INTENDED TO FOSTER EXPANDED EXPORTS AND MARKET DIVERSIFICATION BY ENCOURAGING THE DEVELOPMENT, MAINTENANCE, AND EXPANSION OF DIVERSE COMMERCIAL EXPORT MARKETS FOR UNITED STATES AGRICULTURAL COMMODITIES AND

SBIR PHASE II: HIGH-AFFINITY CYCLODEXTRIN POLYMERS FOR POINT-OF-USE FILTRATION PRODUCTS

SBIR PHASE II: LARGE SCALE CULTIVATION OF PHYTOPLANKTON VIA NOVEL PHOTO-BIOREACTOR TECHNOLOGY

TO CONDUCT APPROVED MARKET DEVELOPMENT ACTIVITIES INTENDED TO FOSTER EXPANDED EXPORTS AND MARKET DIVERSIFICATION BY ENCOURAGING THE DEVELOPMENT, MAINTENANCE, AND EXPANSION OF DIVERSE COMMERCIAL EXPORT MARKETS FOR UNITED STATES AGRICULTURAL COMMODITIES AND

SBIR PHASE II: RAPID, END-TO-END SAMPLE PREPARATION FOR SEQUENCING APPLICATIONS -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT IS THE DEVELOPMENT OF AN INNOVATIVE PLATFORM FOR PREPARING DNA SAMPLES FOR LONG-READ SEQUENCING TECHNOLOGIES. THESE TECHNOLOGIES OFFER UNPRECEDENTED INSIGHTS INTO COMPLEX GENETIC STRUCTURES AND THEIR CONNECTIONS TO HEALTH AND DISEASE BUT REQUIRE LONG, CONTINUOUS DNA STRANDS FOR OPTIMAL PERFORMANCE. CURRENT SAMPLE PREPARATION METHODS ARE LABOR-INTENSIVE AND EXPENSIVE, AND OFTEN COMPROMISE DNA QUALITY AND LENGTH, LIMITING THE UTILITY AND ADOPTION OF LONG-READ SEQUENCERS. THIS PROJECT?S AUTOMATED PLATFORM WILL DELIVER HIGH QUALITY DNA SAMPLES WITH IMPROVED REPRODUCIBILITY, REDUCED PREPARATION TIME, AND LOWER COSTS. BEYOND ADVANCING LONG-READ SEQUENCING, THE PLATFORM WILL ALSO SUPPORT DNA PREPARATION FOR OTHER SEQUENCING (NEXT-GENERATION SEQUENCING) AND ANALYTICAL METHODS, BROADENING ITS IMPACT. THE SEQUENCING SAMPLE PREPARATION MARKET IS A LARGE AND RAPIDLY GROWING MARKET (ANNUAL GROWTH RATE OF 13.4%), WITH LONG-READ SEQUENCING CURRENTLY COMPRISING ~10% OF THE TOTAL MARKET. BY OVERCOMING CRITICAL BARRIERS, THIS INNOVATION WILL ACCELERATE THE ADOPTION OF LONG-READ SEQUENCING, DRIVE MARKET GROWTH, AND CONTRIBUTE TO IMPROVED HEALTH OUTCOMES THROUGH ENHANCED DIAGNOSTICS AND RESEARCH CAPABILITIES. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT AIMS TO RESOLVE A MAJOR CHALLENGE IN GENOMIC SEQUENCING BY ADVANCING A NOVEL TECHNOLOGY FOR HIGH-QUALITY DNA SAMPLE PREPARATION. BUILDING ON SUCCESSFUL PHASE I OUTCOMES, THE PROJECT FOCUSES ON DEVELOPING COMMERCIAL-GRADE PROTOTYPES AND REFINING AN AUTOMATED PLATFORM FOR PREPARING LONG DNA STRANDS. KEY RESEARCH OBJECTIVES INCLUDE FABRICATING USER-FRIENDLY CARTRIDGES AND INSTRUMENTS, IMPROVING PLATFORM PERFORMANCE, AND VALIDATING THE TECHNOLOGY WITH INPUT FROM LEADING RESEARCH INSTITUTIONS. THE APPROACH UTILIZES A PROCESS THAT SELECTIVELY TRAPS GENOMIC MATERIAL IN A MICROSCALE FLOW CELL, WHERE AN ELECTRIC FIELD AND PRESSURE-DRIVEN FLOW WORK IN TANDEM TO ENABLE PURIFICATION AND PREPARATION WITHIN A SINGLE DEVICE. BY THE CONCLUSION OF PHASE II, THE PROJECT AIMS TO DELIVER FULLY OPERATIONAL PROTOTYPES OPTIMIZED FOR COMMERCIALIZATION. THESE INNOVATIONS ARE EXPECTED TO STREAMLINE SAMPLE PREPARATION, SIGNIFICANTLY REDUCING TIME, COST, AND COMPLEXITY WHILE ENHANCING OUTCOMES. THE RESULTING TECHNOLOGY WILL SUPPORT BROADER ADOPTION OF LONG-READ SEQUENCING AND OTHER GENOMIC APPLICATIONS, UNLOCKING NEW POSSIBILITIES IN RESEARCH, HEALTHCARE, AND DIAGNOSTICS. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE PLANNED FOR THIS AWARD.

ESTROGEN FREE POLYMER FORMULATIONS FOR FOOD PACKAGING AND BABY PRODUCTS

SBIR PHASE II: DEVELOPMENT OF AN END-TO-END SOLUTION FOR HIGH-VOLUME WATER MICROBIOLOGICAL TESTING -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT IS TO ENHANCE PUBLIC HEALTH AND SAFETY THROUGH ADVANCED WATER MICROBIOLOGICAL TESTING TECHNOLOGIES. THIS PROJECT'S INNOVATION ENABLES THE EARLY DETECTION OF PANDEMICS BY IDENTIFYING WATERBORNE VIRUSES SUCH AS SARS-COV-2 WHICH CAUSES COVID-19, AND NOROVIRUS, WHICH IS NOTORIOUS FOR CAUSING GASTROENTERITIS, POTENTIALLY WEEKS BEFORE OUTBREAKS MANIFEST. SUCH EARLY DETECTION IS VITAL FOR POLICYMAKERS, ALLOWING MORE EFFECTIVE INTERVENTION STRATEGIES AND REDUCING BOTH HUMAN CASUALTIES AND HEALTHCARE COSTS. MOREOVER, THE TECHNOLOGY PROMISES TO IMPROVE THE SAFETY OF DRINKING WATER, PARTICULARLY IMPORTANT AS MANY STATES INCREASINGLY TURN TO RECYCLING WASTEWATER DUE TO DROUGHT. THIS COULD DECREASE THE INCIDENCE OF WATERBORNE ILLNESSES, WHICH CURRENTLY AFFECT MILLIONS AND COST THE U.S. HEALTHCARE SYSTEM BILLIONS ANNUALLY. ADDITIONALLY, THE INNOVATION FACILITATES MORE ACCESSIBLE AND EFFICIENT WATER TESTING IN REMOTE AND UNDERSERVED COMMUNITIES BY REDUCING COSTS AND PROCESSING TIMES, SUPPORTING HEALTHCARE EQUITY. FINALLY, THIS NEW APPROACH NOT ONLY PROMISES TO TRANSFORM DRINKING WATER SAFETY MONITORING PRACTICES AND WASTEWATER-BASED PANDEMIC SURVEILLANCE BUT ALSO DRIVES THE IMPLEMENTATION OF NEW WATER QUALITY STANDARDS AND REGULATORY FRAMEWORKS, ALIGNING WITH THE BEST AVAILABLE TECHNOLOGY PRACTICES. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT ADDRESSES SIGNIFICANT GAPS IN WATER MICROBIOLOGICAL TESTING. MONITORING THE PRESENCE OF VIRUSES SUCH CORONAVIRUS AND NOROVIRUS IN WATER IS CRUCIAL FOR PANDEMIC SURVEILLANCE AND DRINKING WATER SAFETY. WATERBORNE VIRUSES ARE PRESENT IN LOW CONCENTRATIONS AND THEIR DETECTION REQUIRES THE ANALYSIS OF LARGE SAMPLE VOLUMES. HOWEVER, CURRENT TOOLS ARE DESIGNED FOR SMALL VOLUMES, RESULTING IN LOW SENSITIVITY AND HIGH VARIABILITY IN TESTING RESULTS. THE GOAL OF THIS PROJECT IS TO DEVELOP A COMPREHENSIVE TECHNOLOGICAL SOLUTION TO ENHANCE THE RELIABILITY AND STANDARDIZATION OF WASTEWATER EPIDEMIOLOGY AND DRINKING WATER TESTING, A PRESSING NEED IDENTIFIED BY HEALTH AGENCIES TO IMPROVE DATA QUALITY AND COMPARABILITY. THE CURRENT EFFORT FOCUSES ON DEVELOPING A SCALABLE PLATFORM THAT INTEGRATES A NOVEL FILTRATION CARTRIDGE AND REAGENT KIT, CAPABLE OF PROCESSING UP TO TWO LITERS OF WATER IN LESS THAN FIVE MINUTES. THIS CAPABILITY ENHANCES THE YIELD AND PURITY OF VIRAL NUCLEIC ACIDS AND IMPROVES THE DETECTION LIMIT BY TWO ORDERS OF MAGNITUDE, ENHANCING ACCURACY AND REDUCING FALSE POSITIVES. BY IMPROVING OUR ABILITY TO MONITOR PATHOGEN SPREAD THROUGH COMMUNITY WATER SYSTEMS, THIS PROJECT IS EXPECTED TO ENHANCE PANDEMIC PREPAREDNESS AND DRINKING WATER SAFETY AND FACILITATE MORE EFFECTIVE PUBLIC HEALTH INTERVENTIONS. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE NOT PLANNED FOR THIS AWARD.

COMMUNITY-BASED ABSTINENCE EDUCATION

BABY BOTTLES THAT RELEASE NO CHEMICALS HAVING ESTROGENIC ACTIVITY

REMEDIATION OF PERFLUORINATED CHEMICALS IN WATER USING NOVEL HIGH-AFFINITY POLYMER ADSORBENTS

A HARD AND CLEAR, ESTROGEN-FREE REPLACEMENT FOR BISPHENOL-A BASED POLYCARBONATES

BLOOD AND TISSUE IMMUNOPHENOTYPING IN CANCER PATIENTS TREATED WITH ANTI-GALECTIN-9 MONOCLONAL ANTIBODY (LYT-200) ALONE AND IN COMBINATION WITH ANTI-PD1

COVID RELIEF FOR BIOFUEL PRODUCERS GRANTS

**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** A SORBENT TECHNOLOGY FOR EDNA COLLECTION AND CONCENTRATION FOR AQUACULTURE PATHOGEN DETECTION

SBIR PHASE II: FLEXIBLE PLASTIC PACKAGING WITHOUT ESTROGENIC ACTIVITY (EA)

A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL ALLOPREGNANOLONE (LYT-300) FOR THE TREATMENT OF PREMUTATION CARRIERS WITH FXTAS

HEALTH CENTER CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT FUNDING

CLEAN WATER INNOVATION INITIATIVE (CWII)

REAP ENERGY EFFICIENCY IMPROVEMENT (EEI) GRANT UNRESTRICTED AMOUNT - IRA 24/31

ARRA - CAPITAL IMPROVEMENT PROGRAM

RURAL HEALTH CARE SERVICES OUTREACH GRANT PROGRAM

REAP RENEWABLE ENERGY SYSTEM (RES) GRANT UNRESTRICTED AMOUNT

DATE: JUNE 24, 2024 APPLICANT: PURE BLUE TECH INC. ADDRESS: 1329 MARIETTA AVE, BELLINGHAM, WHATCOM COUNTY, WA 98226 ESTIMATED DURATION: 21 MONTHS ESTIMATED TIMELINE: JANUARY 2025 ? SEPTEMBER 2026 PURE BLUE TECH INC. (PBT) PROPOSES A PROJECT TO PROTOTYPE AND PILOT SENSOR INTEGRATED REVERSE OSMOSIS (SIRO) MEMBRANE ELEMENTS AND A DIGITAL MONITORING SYSTEM TO ENHANCE THE CAPABILITIES OF DESALINATION AND WATER PURIFICATION SYSTEMS. THIS INNOVATION AIMS TO INCREASE THE RESOLUTION AND VOLUME OF CRITICAL DATA BY FOUR TIMES, AIDING SYSTEM OPERATORS IN OPTIMIZING MEMBRANE AND SYSTEM OPERATIONS, RECOVERY, EFFICIENCY, AND MAINTENANCE. THE SIRO TECHNOLOGY INCORPORATES PBT?S PROPRIETARY THIN, FLEXIBLE, FLAT, AND INEXPENSIVE MULTI-SENSOR TECHNOLOGY, ENABLING PRECISE MEASUREMENT AND REPORTING OF WATER QUALITY AND INDIVIDUAL MEMBRANE PERFORMANCE AND HEALTH. IN COLLABORATION WITH THE UNITED STATES BUREAU OF RECLAMATION'S (USBR) WATER QUALITY IMPROVEMENT CENTER (WQIC) IN YUMA, ARIZONA, PBT WILL CONDUCT A 30-90 DAY FIELD PILOT TO EVALUATE THE SIRO TECHNOLOGY'S PERFORMANCE, INSTALLATION, AND USABILITY. DATA MEASURED AND MONITORED BY THE SYSTEM WILL INCLUDE CRITICAL MEMBRANE ELEMENT AND SYSTEM PERFORMANCE, HEALTH, PRODUCTIVITY, EFFICIENCY, AND RECOVERY INFORMATION--DATASETS CURRENTLY UNAVAILABLE WITHIN PRESSURE VESSELS. THIS PROJECT WILL SIGNIFICANTLY IMPROVE REAL-TIME DATA ACQUISITION, SUPPORTING OPERATORS IN OPTIMIZING RESOURCE USAGE, PROCESS CONTROL, MAINTENANCE, AND CLEANING PROCEDURES BY ENHANCING DECISION SUPPORT WITH HIGHER RESOLUTION DATA AND NEW DATA. IT ALSO AIMS TO PROVIDE INTELLIGENCE REGARDING MEMBRANE FOULING AND SCALING AND IDENTIFY FAILED MEMBRANE ELEMENTS WITHIN LARGE-SCALE OPERATIONS. INSTANTANEOUS AND AUTOMATIC DETECTION OF BREACHES OF PFAS AND OTHER TOXIC CONTAMINANTS INTO THE PERMEATE STREAM WILL BE ENABLED. THE INTEGRATION OF REAL-TIME DATA ACQUISITION SOFTWARE WILL FACILITATE EVALUATION AND DECISION-MAKING FROM THE DATASETS. COLLECTIVELY, THIS HELPS MODERNIZE THE DESALINATION, WATER PURIFICATION, AND WASTEWATER TREATMENT INDUSTRY NATIONWIDE AND ADVANCE USA'S LEADERSHIP GLOBALLY. THE TOTAL PROJECT COST IS $615,432.91, WITH PBT REQUESTING $300,000 IN CASH REIMBURSEMENT FUNDING FROM USBR, AND THE REMAINING $315,432.91 FUNDED THROUGH PBT?S EQUITY INVESTMENTS. THE PROJECT IS SET TO COMMENCE IN JANUARY 2025, WITH A COMPLETION DATE OF SEPTEMBER 2026, INCLUDING 3 MONTHS FOR PRE-AWARD ACTIVITIES AND A 6-MONTH BUFFER FOR POTENTIAL DELAYS. THE WORK WILL BE CONDUCTED AT PBT?S HEADQUARTERS IN BELLINGHAM, WA, AND USBR?S WATER QUALITY IMPROVEMENT CENTER IN YUMA, AZ. THE COLLABORATORS ARE CONFIDENT THIS PROJECT ADVANCES USBR'S MISSION OF ADVANCING WATER SUPPLIES IN THE WESTERN U.S. BY EQUIPPING MEMBRANE-BASED WATER TREATMENT FACILITIES WITH HIGHER RESOLUTION DATA AND INTELLIGENCE TO OPTIMIZE OPERATIONS. BENEFICIARIES INCLUDE THE UNITED STATES GOVERNMENT, MUNICIPALITIES, INDUSTRIAL MANUFACTURERS, DESALINATION AND WASTEWATER TREATMENT FACILITIES, AND THE GENERAL PUBLIC.

THIS PROJECT INVOLVES THE MANUFACTURING AND FIELD PILOTING OF NOVEL ANTI-FOULING NANOPATTERNED ULTRASONIC REVERSE OSMOSIS MEMBRANE ELEMENTS FOR EFFICIENT, HIGH-RECOVERY DESALINATION OF BRACKISH WATER AND PURIFICATION OF SURFACE WATER. THE PROPOSED NANOPATTERNED ULTRASONIC REVERSE OSMOSIS IS A NEW SPIRAL WOUND MEMBRANE ELEMENT THAT INCLUDES MEMBRANE WITH NANOSCALE SURFACE IMPRINTS AND A LOW-WATTAGE, THIN, AND FLEXIBLE ULTRASOUND TRANSDUCER SPIRALLY WOUND WITH COMMERCIAL OFF-THE-SHELF ELEMENT COMPONENTS. THESE INNOVATIONS INSIDE THE NANOPATTERNED ULTRASONIC REVERSE OSMOSIS ENABLE THE MEMBRANE ELEMENT TO RESIST MEMBRANE FOULING, SCALING, AND CONCENTRATION POLARIZATION BY INCREASING NANOSCALE AND MACRO TURBULENCE AND MIXING AT THE MEMBRANE BOUNDARY LAYER AND PREEMPTIVELY, CONTINUOUSLY DELAY AND REDUCE FOULING, SALT PRECIPITATION, AND CONCENTRATION POLARIZATION. AS A RESULT, THIS MEMBRANE ELEMENT CAN INCREASE SUSTAINED FLUX, REDUCE PRESSURE DROP, REDUCE CHEMICAL CLEANINGS, AND INCREASE RECOVERY.

SBIR PHASE I: A VERSATILE NUCLEIC ACID COLLECTION AND PURIFICATION TECHNOLOGY FOR WASTEWATER-BASED EPIDEMIOLOGY -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT IS TO PROVIDE PRIVATE AND PUBLIC STAKEHOLDERS WITH NEW TECHNOLOGICAL TOOLS TO BETTER MONITOR AND PREDICT PANDEMICS. THIS PROJECT IS EXPECTED TO MODERNIZE THE TOOLS USED TODAY BY PRIVATE AND PUBLIC LABORATORIES TO COLLECT AND PURIFY PATHOGENS, PARTICULARLY HUMAN CORONAVIRUSES FROM COMMUNITY WASTEWATER, FOR TESTING AND DIAGNOSTIC PURPOSES. THE NEW TECHNOLOGICAL TOOLS ARE EXPECTED TO SIMPLIFY THE WORKFLOW, REDUCE COSTS AND TIME, AND ENABLE THE PREDICTION OF COVID-19 OUTBREAKS AND OTHER PANDEMICS SEVERAL WEEKS BEFORE OBSERVING CLINICAL CASES. SUCH EARLY PREDICTION WOULD PROVIDE THE PUBLIC AND GOVERNMENT AGENCIES WITH IMPORTANT DATA AND SUFFICIENT TIME TO TAKE PREVENTIVE MEASURES. THE TECHNOLOGICAL PRODUCTS OF THIS PROJECT ARE EXPECTED TO EMPOWER THE GROWING NUMBER OF COMPANIES AND LABORATORIES OFFERING WASTEWATER-BASED EPIDEMIOLOGY (WBE) SERVICES AND HELP ESTABLISH WBE AS A ROUTINE, COST-EFFECTIVE AND RELIABLE TOOL FOR PUBLIC HEALTH MONITORING. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT WILL ADDRESS A MAJOR TECHNOLOGICAL BARRIER FOR THE DETECTION OF VIRUSES SUCH AS SARS-COV-2 IN WASTEWATER. COMMERCIALLY AVAILABLE NUCLEIC ACID COLLECTION AND PURIFICATION KITS ARE DESIGNED FOR CLINICAL SAMPLES WITH SMALL VOLUMES. THESE KITS ARE NOT GENERALLY USED FOR LARGE WASTEWATER VOLUMES WHERE THE VIRUS IS PRESENT AT LOW CONCENTRATIONS. AS A RESULT, CURRENT PROCESSES ARE TIME-CONSUMING, AND RESULT IN THE RECOVERY OF LESS THAN 30% OF VIRUSES AND NUCLEIC ACIDS, SIGNIFICANTLY REDUCING THE SENSITIVITY. THE GOAL OF THIS SBIR PHASE I PROJECT IS TO DEMONSTRATE THE FEASIBILITY OF A NOVEL VIRUS AND NUCLEIC ACID COLLECTION AND PURIFICATION TECHNOLOGY FROM WASTEWATER. SPECIFICALLY, THE PROJECT TASKS AIM AT ENHANCING UNDERSTANDING OF VIRUS PROPERTIES, PARTICULARLY HUMAN CORONAVIRUSES IN WASTEWATER AND THEIR INTERACTIONS WITH FILTER MEDIA. THE PROJECT?S INNOVATIVE APPROACH IS TO DESIGN A STREAMLINED WORKFLOW THAT INCLUDES ALL THE STEPS FROM SAMPLE COLLECTION TO DETECTION, IN A SINGLE DISPOSABLE CARTRIDGE CONTAINING NOVEL FILTERS WITH HIGH AFFINITY TO VIRUSES. THIS DEVELOPMENT IS EXPECTED TO ENHANCE VIRAL AND NUCLEIC ACID RECOVERY IN WASTEWATER TO OVER 90%, WHILE REDUCING COSTS. THE DEVELOPED TOOLS WILL BE INDEPENDENTLY TESTED AND EVALUATED BY THIRD-PARTY LABORATORIES TO CONFIRM THEIR PERFORMANCE. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.

A GEL-LESS, BEAD-LESS GENOMIC SIZE SELECTION APPROACH ON A RAPID AND INEXPENSIVE MICROFLUIDIC SAMPLE PREPARATION PLATFORM - ABSTRACT LONG-READ SEQUENCING IS REVOLUTIONIZING GENOMICS BY ENABLING THE ANALYSIS OF MUCH LARGER DNA FRAGMENTS (>10 KB), UNLIKE TRADITIONAL SHORT-READ SEQUENCING THAT PROCESSES SMALLER FRAGMENTS. THIS CAPABILITY RESOLVES COMPLEX GENOMIC REGIONS SUCH AS REPETITIVE SEQUENCES, STRUCTURAL VARIATIONS, AND LONG-RANGE HAPLOTYPES OFTEN INACCESSIBLE WITH SHORT READS. LONG-READ TECHNOLOGIES, SUCH AS PACBIO AND OXFORD NANOPORE (ONT), EXCEL IN CAPTURING COMPLEX GENOMIC FEATURES BUT ARE MOST IMPACTFUL WHEN PROCESSING LARGER DNA MOLECULES. AS THESE METHODS IMPROVE IN COST AND ACCURACY, THEIR ADOPTION IS POISED TO ACCELERATE, ADVANCING OUR UNDERSTANDING OF GENOMIC ARCHITECTURE AND ITS RELEVANCE TO HEALTH AND DISEASE. HOWEVER, SAMPLE PREP, PARTICULARLY SIZE SELECTION, REMAINS A MAJOR BOTTLENECK FOR BOTH SEQUENCING METHODS. CURRENT TECHNIQUES, RELYING ON BEADS AND GELS, ARE LABOR-INTENSIVE, ERROR-PRONE, AND COSTLY, HEIGHTENING RISKS OF SAMPLE LOSS AND CONTAMINATION. ACCURATE SIZE SELECTION IS CRUCIAL, ESPECIALLY FOR PACBIO, WHERE FRAGMENT SIZES UNDER 10 KB COMPROMISE PERFORMANCE. TO ADDRESS THIS, MICROPURE GENOMICS INC. PROPOSES AN AUTOMATED, BEAD-LESS, GEL-LESS MICROFLUIDIC SIZE SELECTION APPROACH. THIS INNOVATION SIMPLIFIES WORKFLOWS, REDUCES COSTS, IMPROVES REPRODUCIBILITY, AND ENHANCES SEQUENCING PERFORMANCE, PAVING THE WAY FOR ACCURATE AND COMPREHENSIVE GENOMIC ANALYSES. USING PATENTED ELECTRO-HYDRODYNAMIC (EH) TRAPPING TECHNOLOGY, THE ΜPREP ENABLES GENTLE PURIFICATION AND MICROFLUIDIC HANDLING WITHOUT BEADS, MINIMIZING SAMPLE DEGRADATION. VALIDATED FOR ONT PROTOCOLS, ΜPREP REDUCES PREP TIME (>50%), COSTS (>30%), AND COMPLEXITY (>90%), WHILE IMPROVING ACCURACY. THESE ADVANCEMENTS PROMISE TO EXPAND LONG-READ SEQUENCING ADOPTION, DRIVING GENOMIC RESEARCH AND CLINICAL APPLICATIONS. THIS PHASE I PROPOSAL SEEKS TO EXTEND ΜPREP'S CAPABILITIES TO SUPPORT PACBIO, WHOSE HIGH-THROUGHPUT REVIO SEQUENCER DEMANDS PRECISE SAMPLE PREP. WE WILL DEVELOP AND INTEGRATE EH-BASED SIZE SELECTION FOR PACBIO WORKFLOWS, TARGETING GENOMIC FRAGMENTS (18 KB AND PACBIO-PREPARED DNA). STRONG PRELIMINARY RESULTS WILL GUIDE EFFORTS TO DEMONSTRATE FEASIBILITY, STREAMLINE WORKFLOWS, AND ENHANCE COMPATIBILITY WITH EXISTING PLATFORMS. SPECIFIC AIMS INCLUDE: 1. DEVELOPMENT OF THE EH TRAPPING FOR GENOMIC SIZE SEPARATION AND SELECTION. 2. SIZE SELECTION FOR 18 KB DNA. 3. SIZE SELECTION OF PACBIO LIBRARY-PREPARED DNA USING EH TRAPPING. PHASE II WILL FULLY INTEGRATE THE SAMPLE PREP PROCESS INTO A SCALABLE CARTRIDGE, FACILITATING COMMERCIAL VALIDATION AND ADOPTION. ULTIMATELY, THIS INNOVATION WILL ENHANCE SEQUENCING WORKFLOWS AND ACCELERATE BREAKTHROUGHS IN GENOMIC SCIENCE AND CLINICAL DIAGNOSTICS.

REMEDIATION OF PERFLUORINATED CHEMICALS IN WATER USING NOVEL HIGH-AFFINITY POLYMER ADSORBENTS - ABSTRACT CONTAMINATION OF WATER SUPPLIES BY TOXIC PER- AND POLYFLUOROALKYL SUBSTANCES IS A MAJOR HEALTH AND ENVIRONMENTAL ISSUE IMPACTING SOCIETY TODAY. GIVEN THE ENVIRONMENTAL PERSISTENCE OF THESE CONTAMINANTS AND THEIR ESTABLISHED LINKAGE TO SERIOUS HEALTH RISKS, IT IS IMPERATIVE THAT SAFE, EFFICIENT, AND COST-EFFECTIVE PFAS REMEDIATION TECHNOLOGIES BE DEVELOPED THAT CAN ELIMINATE THESE CONTAMINANTS FROM THE U.S. WATER SUPPLIES. WITH THE TIGHTENING OF HEALTH-BASED CONTAMINATION LIMITS AND THE EXPANSION OF REGULATED PFAS STRUCTURES, THE IMPACTS OF PFAS CONTAMINATION ARE NOW ESTIMATED TO AFFECT OVER 200 MILLION AMERICANS. NIEHS SPONSORED DEXSORB ADSORBENT REPRESENTS A BREAKTHROUGH SOLUTION FOR THE SAFE, RAPID, AND COST-EFFECTIVE REMOVAL OF SHORT- AND LONG- CHAIN PFAS COMPOUNDS, INCLUDING PFOA AND PFOS FROM WATER. IT TAKES EXACTING TECHNOLOGY TO REMOVE PFAS COMPOUNDS AT THE TRACE LEVELS BEING MANDATED BY STATES AND THE EPA. MADE FROM RENEWABLE CYCLODEXTRINS, DEXSORB’S ABILITY TO SELECTIVELY TARGET PFAS COMPOUNDS AT TRACE CONCENTRATIONS WITH RAPID UPTAKE, HIGH CAPACITY, AND RESISTANCE TO FOULING MAKE IT IDEALLY SUITED FOR USE IN PRIVATE AND MUNICIPAL WATER TREATMENT SYSTEMS. WORKING WITH ENVIRONMENTAL PARTNERS, CYCLOPURE HAS DEMONSTRATED THE SUPERIOR PERFORMANCE AND FAVORABLE LIFE CYCLE ECONOMIES OF DEXSORB IN PILOT WATER TREATMENT ACTIVITIES. TO ADVANCE FURTHER, SPECIFIC MILESTONES THAT UPON COMPLETION WILL HELP CYCLOPURE TRANSITION TO FULL COMMERCIALIZATION STAGE HAVE BEEN IDENTIFIED IN THIS CRP PROPOSAL. CYCLOPURE’S MAIN OBJECTIVE IN THIS PROGRAM WILL BE TO SEEK SUPPORT FOR REGULATORY AND MANUFACTURING ASSISTANCE. BOTH AREAS ARE CRITICAL PRIOR TO THE COMMENCEMENT OF FULL-SCALE MANUFACTURING AND COMMERCIALIZATION ACTIVITIES. SAFETY AND HEALTH RELATED INFORMATION AND ASSOCIATED EXPERIMENTAL DATA WILL BE COLLECTED AND ORGANIZED FOR MATERIAL REGISTRATIONS AND CERTIFICATIONS AS REQUIRED BY REGULATORY AGENCIES INCLUDING EPA AND NSF INTERNATIONAL. ACTIVITIES UNDER MANUFACTURING ASSISTANCE WILL SUPPORT DEVELOPING AN OPTIMAL PURIFICATION METHOD THAT IS EXPECTED TO PROVIDE SIGNIFICANT COST AND PROCESS IMPROVEMENTS IN A FULL-SCALE MANUFACTURING ENVIRONMENT. SUCCESSFUL COMPLETION OF THIS PROPOSED WORK WILL ENABLE CYCLOPURE TO TRANSITION TO LARGE-SCALE PRODUCTION AND WORK WITH INDUSTRY PARTNERS TO MAKE DEXSORB AVAILABLE TO PROVIDE PFAS REMOVAL FOR CONSUMER AND MUNICIPAL APPLICATIONS.

SBIR PHASE I: RAPID, END-TO-END SAMPLE PREPARATION FOR SEQUENCING APPLICATIONS -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT CONSISTS OF ADVANCING METHODS FOR PREPARING DEOXYRIBONUCLEIC ACID (DNA) FOR SEQUENCING. PRIOR TO SEQUENCING A BIOLOGICAL SAMPLE, DNA MUST BE LIBERATED FROM CELLS AND SEPARATED FROM PROTEINS AND OTHER UNWANTED DEBRIS, AND THEN MIXED WITH SPECIALTY BUFFERS AND CHEMICAL AGENTS. THIS SKILLED TASK IS CURRENTLY CARRIED OUT BY TRAINED SCIENTISTS USING LARGELY MANUAL MANIPULATIONS OF THE SAMPLES AND EXPENSIVE EQUIPMENT. THE ALTERNATIVE METHOD PROPOSED IN THIS PROJECT WILL SPEED-UP DIAGNOSES FROM GENOMIC SEQUENCING BY SIGNIFICANTLY REDUCING PREPARATION TIME WHILE ALSO MAKING PREPARATION MORE RELIABLE THROUGH AUTOMATION. NOTABLY, THE PROPOSED APPROACH IS EXPECTED TO PREPARE DNA WITHOUT REDUCING ITS LENGTH; CONSEQUENTLY, THE PROCESS SHOULD BE IDEALLY SUITED FOR PREPARING SAMPLES FOR EMERGING LONG-READ SEQUENCING TECHNOLOGIES. THESE IMPROVEMENTS HAVE THE POTENTIAL TO DECREASE THE BURDEN AND COSTS ASSOCIATED WITH DNA SEQUENCING, HENCE EXPANDING THE BENEFITS OF DNA SEQUENCING TECHNOLOGY TO WIDER SEGMENTS OF SOCIETY. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT RELIES UPON A PROCESS FOR TRAPPING GENOMIC MATERIAL IN A SMALL FLOW CELL THROUGH WHICH AN ELECTRIC FIELD AND PRESSURE-DRIVEN FLOW ARE SIMULTANEOUSLY APPLIED. THE PROCESS IS HIGHLY SELECTIVE TOWARDS STRANDS OF DNA OR (RIBONUCLEIC ACID) RNA; PROTEINS AND OTHER, UNWANTED DEBRIS THAT ENTERS THE FLOW CELL PASSES THROUGH. ALSO, THE PROCESS IS RELATIVELY GENTLE, SO THE LENGTH OF SAMPLE SHOULD NOT BE SHORTENED AS A RESULT. THIS PROJECT WILL ADVANCE THE TECHNOLOGY TO THE MARKETPLACE BY: (1) COMPLETING CARTRIDGE DESIGN DETAILS AND FABRICATION, INCLUDING EVALUATION OF MATERIAL OPTIONS; (2) BUILDING A CUSTOM RESEARCH AND DEVELOPMENT PLATFORM FOR INTERFACING WITH THE CARTRIDGES; (3) DEVELOPING METHODS FOR DNA SAMPLE EXTRACTION AND TRANSFER; (4) DEVELOPING THE LIBRARY PREPARATION PROTOCOLS USING MIXING AND HEATING WHILE TOGGLING THE ELECTRO-HYDRODYNAMIC TRAPPING; AND, (5) INTEGRATING THE ENTIRETY OF THE PREPARATION PROCESS INTO A SINGLE CARTRIDGE AND VALIDATING THE PROCESS PERFORMANCE. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.

REAP RENEWABLE ENERGY SYSTEM (RES) GRANT UNRESTRICTED AMOUNT

SBIR PHASE I: ALGAE CULTIVATION TECHNOLOGY FOR VALUE ADDED CO-PRODUCTS FROM WASTE WATER TREATMENT EFFLUENT -THE BROADER IMPACTS OF THIS SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PHASE I PROJECT IS TO IMPROVE REUSE OF WASTEWATER. THIS PROJECT ADVANCES A NEW ALGAE REACTOR TO REDUCE BIOLOGICAL NUTRIENT POLLUTION. THIS WILL IMPROVE HEALTH, POTENTIAL LOSS OF COMMERCIAL FISHING RESOURCES, WATER TOURISM, AND PROPERTY VALUE DECLINE. THE DIVERSITY OF PRODUCTS THAT CAN BE GENERATED FROM ALGAE CULTIVATION IMPROVE THE ROBUSTNESS OF THE GLOBAL FOOD CHAIN AND THE SECURITY OF DOMESTIC FEEDSTOCKS, E.G. HIGH NUTRITION FEEDS FOR LIVESTOCK AND AQUACULTURE AND A NEW SOURCE OF CHEMICALS AND BIOFUELS. THE PROPOSED DESIGN FOR MAXIMUM RESOURCE EFFICIENCY IN WATER AND ENERGY ENABLES VALUE EXTRACTION FROM MARGINAL LANDS. THE PROPOSED PROJECT AIMS TO REDUCE LEVELS OF BIOLOGICAL NUTRIENT POLLUTANTS IN THE EFFLUENT OF WASTEWATER TREATMENT FACILITIES?BY THE DEVELOPMENT OF AN INDUSTRIAL SCALE, ALGAE PHOTOBIOREACTOR, DESIGNED TO OPERATE IN A HIGH-VOLUME, CONTINUOUS FLOW PROCESS. ANTICIPATED ADVANTAGES OF THE NEW TECHNOLOGY ARE A REDUCTION IN CAPITAL AND OPERATING EXPENSE COMPARED TO EXISTING NUTRIENT REMOVAL METHODS AND THE CAPACITY TO GENERATE, HIGH-PURITY, ALGAE COPRODUCTS WITH COMMERCIAL VALUE. RESEARCH OBJECTIVES INCLUDE THE FOLLOWING: (1) CREATE A COMPUTATIONAL FLUID DYNAMICS (CFD) MODEL OF THE REACTOR UNDER VARIOUS FLOW CONDITIONS; (2) PERFORM DYE TRACER EXPERIMENTS IN THE REACTOR AS VALIDATION OF THE MODELING RESULTS; (3) INSTALL THE REACTOR AS PART OF AN INTEGRATED NUTRIENT REMOVAL SYSTEM INCLUDING ULTRAFILTRATION, PRODUCT RECYCLE STREAM, NUTRIENT SENSORS AND PROCESS FEEDBACK CONTROL; (4) EVALUATE THE NUTRIENT REMOVAL CAPABILITIES OF THE SYSTEM USING A LIVE ALGAE CULTURE AND EFFLUENT FROM AN ADJACENT WASTEWATER TREATMENT FACILITY; AND (5) PERFORM A TECHNOECONOMIC ANALYSIS OF THE PROPOSED PROCESS. RESULTS OF THE PROJECT WILL PROVIDE A BETTER UNDERSTANDING OF THE EFFECT OF REACTOR DESIGN AND OPERATING PARAMETERS ON THE HYDRAULIC AND SOLIDS RESIDENCE TIME DISTRIBUTIONS, HOW THESE INFLUENCE THE WASTE REMOVAL PERFORMANCE OF THE SYSTEM, AND WHAT DESIGN PARAMETERS EXERT THE MOST CONTROL OVER ECONOMIC FEASIBILITY. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.

SBIR PHASE I: ZERO EMISSION NESTED LOOP REFORMING FOR HIGH PURITY HYDROGEN PRODUCTION

SBIR PHASE I: POROUS CYCLODEXTRIN POLYMERS: A SUSTAINABLE AND HIGHLY EFFECTIVE PLATFORM FOR WATER TREATMENT

EROSION CONTROL

A HARD AND CLEAR, ESTROGEN-FREE REPLACEMENT FOR BISPHENOL-A BASED POLYCARBONATES

ARRA - INCREASE SERVICES TO HEALTH CENTERS

VALUE- ADDED AGRICULTURAL PRODUCT MARKET DEVELOPMENT GRANTS

SBIR PHASE I: FLEXIBLE PLASTIC PACKAGING WITHOUT ESTROGENIC ACTIVITY (EA)

SBIR PHASE I: LARGE SCALE CULTIVATION OF PHYTOPLANKTON VIA NOVEL PHOTO-BIOREACTOR TECHNOLOGY

GRANT FOR PROD OF ADV BIOFUEL

REMEDIATION OF PERFLUORINATED CHEMICALS IN WATER USING NOVEL HIGH-AFFINITY POLYMER ADSORBENTS

ESTROGEN FREE POLYMER FORMULATIONS FOR FOOD PACKAGING AND BABY PRODUCTS

GRANT FOR PROD OF ADV BIOFUEL

FY 2023 EXPANDING COVID-19 VACCINATION

LAMP BEGINNING AND SOCIALLY DISADVANTAGED FARMERS OR RANCHERS--MANDATORY

RBDG RURAL BUSINESS COOP RURAL ENTERPRISE GRANT

VALUE- ADDED AGRICULTURAL PRODUCT MARKET DEVELOPMENT GRANTS

A SORBENT TECHNOLOGY FOR EDNA COLLECTION AND CONCENTRATION FOR AQUACULTURE PATHOGEN DETECTION

HEALTH CARE AND OTHER FACILITIES

FY 2020 EXPANDING CAPACITY FOR CORONAVIRUS TESTING (ECT)

RCDG - VALUE-ADDED PRODUCT MARKET DEVELOPMENT GRANTS

COVID RELIEF FOR BIOFUEL PRODUCERS GRANTS

GRANT FOR PROD OF ADV BIOFUEL

GRANT FOR PROD OF ADV BIOFUEL

GRANT FOR PROD OF ADV BIOFUEL

PURPOSE: TO SUPPORT A TOURING PRODUCTION OF SEPTIMA BY PATRICIA DOCKERY.

FY 2020 CORONAVIRUS SUPPLEMENTAL FUNDING FOR HEALTH CENTERS

RCDG - VALUE-ADDED PRODUCT MARKET DEVELOPMENT GRANTS

SEC. 9007 REAP-RENEW ENERGY SYS GRANTS (MAN)

RCDG - VALUE-ADDED PRODUCT MARKET DEVELOPMENT GRANTS

TO SUPPORT A U.S-BASED DANCE GROUP IN VISITING THE DRC FOR WORKSHOPS AND PERFORMANCES.

DISC VALUE-ADDED AG PMDG-BEG & SOC DISADV FARMERS & RANCHERS

SEC. 9007 REAP-RENEW ENERGY SYS GRANTS (MAN)

THIS GRANT SUPPORTS THE COSTS INCURRED TO IMPLEMENT MEASURES TO RESPOND TO THE NOVEL CORONAVIRUS 2019 (COVID-19), WHICH MAY INCLUDE WORKPLACE SAFETY, MARKET PIVOTS, RETROFITTING FACILITIES, TRANSPORTATION, WORKER HOUSING, AND MEDICAL EXPENSES. IT PROVIDES NEEDED RELIEF TO THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS FOR THEIR COSTS INCURRED BETWEEN JANUARY 27, 2020, THE DATE UPON WHICH THE PUBLIC HEALTH EMERGENCY WAS DECLARED BY THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICE (HHS) UNDER SECTION 319 OF THE PUBLIC HEALTH SERVICE ACT, AND DECEMBER 31, 2021. BENEFICIARIES INCLUDE THE EMPLOYEES OF THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS.

FY 2023 BRIDGE ACCESS PROGRAM

BEE BLESSED PURE HONEY - PANDEMIC RESPONSE AND SAFETY GRANTS PROGRAM APPLICATION

CARES GRANT

CARES GRANT

ON MAY 13, 2021, HEERF III FUNDS WERE MADE AVAILABLE TO RELIEVE SOME OF THE FINANCIAL STRAIN FROM STUDENTS DURING THE PANDEMIC. PURE AESTHETICS WAS ALLOCATED $AZ-00216,189.00

THIS GRANT SUPPORTS THE COSTS INCURRED TO IMPLEMENT MEASURES TO RESPOND TO THE NOVEL CORONAVIRUS 2019 (COVID-19), WHICH MAY INCLUDE WORKPLACE SAFETY, MARKET PIVOTS, RETROFITTING FACILITIES, TRANSPORTATION, WORKER HOUSING, AND MEDICAL EXPENSES. IT PROVIDES NEEDED RELIEF TO THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS FOR THEIR COSTS INCURRED BETWEEN JANUARY 27, 2020, THE DATE UPON WHICH THE PUBLIC HEALTH EMERGENCY WAS DECLARED BY THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICE (HHS) UNDER SECTION 319 OF THE PUBLIC HEALTH SERVICE ACT, AND DECEMBER 31, 2021. BENEFICIARIES INCLUDE THE EMPLOYEES OF THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS.

THIS GRANT SUPPORTS THE COSTS INCURRED TO IMPLEMENT MEASURES TO RESPOND TO THE NOVEL CORONAVIRUS 2019 (COVID-19), WHICH MAY INCLUDE WORKPLACE SAFETY, MARKET PIVOTS, RETROFITTING FACILITIES, TRANSPORTATION, WORKER HOUSING, AND MEDICAL EXPENSES. IT PROVIDES NEEDED RELIEF TO THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS FOR THEIR COSTS INCURRED BETWEEN JANUARY 27, 2020, THE DATE UPON WHICH THE PUBLIC HEALTH EMERGENCY WAS DECLARED BY THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICE (HHS) UNDER SECTION 319 OF THE PUBLIC HEALTH SERVICE ACT, AND DECEMBER 31, 2021. BENEFICIARIES INCLUDE THE EMPLOYEES OF THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS.

TO SUPPORT THE CREATION AND PRESENTATION OF NEW WORKS BY ARTISTIC DIRECTOR RENNIE HARRIS.

THIS GRANT SUPPORTS THE COSTS INCURRED TO IMPLEMENT MEASURES TO RESPOND TO THE NOVEL CORONAVIRUS 2019 (COVID-19), WHICH MAY INCLUDE WORKPLACE SAFETY, MARKET PIVOTS, RETROFITTING FACILITIES, TRANSPORTATION, WORKER HOUSING, AND MEDICAL EXPENSES. IT PROVIDES NEEDED RELIEF TO THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS FOR THEIR COSTS INCURRED BETWEEN JANUARY 27, 2020, THE DATE UPON WHICH THE PUBLIC HEALTH EMERGENCY WAS DECLARED BY THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICE (HHS) UNDER SECTION 319 OF THE PUBLIC HEALTH SERVICE ACT, AND DECEMBER 31, 2021. BENEFICIARIES INCLUDE THE EMPLOYEES OF THE FOOD PROCESSORS, DISTRIBUTORS, FARMERS MARKETS, AND PRODUCERS.

SEC. 9007 REAP-ENERGY EFFICIENCY IMPROVEMENTS GRANTS (MAN)

TRIPAR ALGAE CULTIVATION TECHNOLOGY FOR VALUE ADDED CO-PRODUCTS FROM WWT EFFLUENT

WOOD STRAW - PUTTING IT TO USE